Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gadoteric Acid→

Gadoteric Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
72573-82-1
Molecular formula
C16H25GdN4O8
Molecular weight
558.65 g/mol
Drug class
Macrocyclic gadolinium-based paramagnetic MRI contrast agent
Mechanism of action
A macrocyclic gadolinium chelate that shortens the T1 and T2 relaxation times of nearby water protons in a magnetic field, increasing signal intensity in MRI.
Indications / reported uses
  • Contrast enhancement in MRI of the brain, spine and other body regions where disruption of the blood-brain barrier or abnormal vascularity is being evaluated, according to the product label.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/158536 · https://www.gov.uk/drug-safety-update/gadolinium-containing-contrast-agents-removal-of-omniscan-and-iv-magnevist-restrictions-to-the-use-of-other-linear-agents

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gadoteric Acid Environmental Risk Assessment (ERA) (the Gadoteric Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.